Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Adjuvant treatment early HER+ in breast cancer

How low should we go? Treatment for stage I HER2+ disease


08 May 2021


Adjuvant treatment early HER+ in breast cancer


Sara Tolaney


S. Tolaney

Author affiliations

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston/US


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings